Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Prothena Corporation plc - Ordinary Shares
(NQ:
PRTA
)
9.470
+0.090 (+0.96%)
Streaming Delayed Price
Updated: 12:19 PM EST, Dec 19, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Prothena Corporation plc - Ordinary Shares
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
March 15, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for...
Via
FinancialNewsMedia
Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting
March 14, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights
February 23, 2023
From
Prothena Corporation plc
Via
Business Wire
Earnings Outlook For Prothena Corp
↗
February 22, 2023
Via
Benzinga
Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate
↗
February 01, 2023
Via
Benzinga
Analyst Expectations for Prothena Corp's Future
↗
December 21, 2022
Via
Benzinga
Earnings Scheduled For February 23, 2023
↗
February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Via
Benzinga
Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
February 16, 2023
From
Prothena Corporation plc
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
February 14, 2023
Via
Benzinga
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2023
From
Prothena Corporation plc
Via
Business Wire
Cantor Fitzgerald Maintains Overweight Rating for Prothena Corp: Here's What You Need To Know
↗
December 21, 2022
Via
Benzinga
What 4 Analyst Ratings Have To Say About Prothena Corp
↗
November 04, 2022
Within the last quarter, Prothena Corp (NASDAQ:PRTA) has observed the following analyst ratings:
Via
Benzinga
Recap: Prothena Corp Q3 Earnings
↗
November 03, 2022
Prothena Corp (NASDAQ:PRTA) reported its Q3 earnings results on Thursday, November 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
January 31, 2023
From
Prothena Corporation plc
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
↗
January 27, 2023
Via
Benzinga
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish
↗
January 11, 2023
2023 can be the year of biotechs after two consecutive years of negative or barely positive returns.
Via
Talk Markets
How To Weather These Choppy Markets
↗
December 22, 2022
Until we get an absolute bottom in the markets, the best way to avoid experiencing a devastating permanent loss of capital is to keep away from stocks with deteriorating fundamentals and heavy insider...
Via
Talk Markets
Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease
↗
December 21, 2022
The estimated cost of Alzheimer's disease and related dementia (ADRD) care in 2021 was $355 billion. Investing in the top companies that are making steady progress toward developing a treatment for...
Via
Talk Markets
Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares
December 14, 2022
From
Prothena Corporation plc
Via
Business Wire
Why Prothena Shares Are Trading Lower
↗
December 14, 2022
Prothena Corporation PLC (NASDAQ: PRTA) shares are trading lower by 6.53% to $59.10 during Wednesday morning. The company announced that it has commenced an underwritten public offering of 3,000,000 of...
Via
Benzinga
Why Prothena Shares Are Nosediving During Tuesday's After-Hours Session
↗
December 13, 2022
Prothena Corporation PLC (NASDAQ: PRTA) shares are trading lower by some 8.35% to $57.95 during Tuesday's after-hours session. The company announced that it has commenced an underwritten public...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
December 13, 2022
Via
Benzinga
Prothena Announces Proposed Public Offering of Ordinary Shares
December 13, 2022
From
Prothena Corporation plc
Via
Business Wire
Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022
December 12, 2022
From
Prothena Corporation plc
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
↗
November 22, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy
November 21, 2022
From
Prothena Corporation plc
Via
Business Wire
Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others
↗
November 14, 2022
Biogen rose on Roche's Alzheimer's failure as a potential competitor drops off the map.
Via
Investor's Business Daily
Prothena Reports Third Quarter 2022 Financial Results and Business Highlights
November 03, 2022
From
Prothena Corporation plc
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
↗
November 04, 2022
Upgrades
Via
Benzinga
Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 Meeting
November 03, 2022
From
Prothena Corporation plc
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today